StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) company profile

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.49+0.62 (+2.22%)

Close on Nov 17, 2026Market cap $4.55BP/E –Yield –

About Adaptive Biotechnologies

Biological Products, (No Diagnostic Substances), SIC 2836

Adaptive Biotechnologies Corporation operates an immune medicine platform that decodes the adaptive immune system to diagnose and treat diseases. The company is organized into two primary segments: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business. In its MRD division, the company provides the clonoSEQ diagnostic test to measure residual disease burden in lymphoid malignancies, serving clinicians in healthcare settings and biopharmaceutical companies conducting clinical drug development trials. The IM business sequences, maps, and characterizes immune receptors, offering solutions such as immunosequencing services, data licensing, predictive models, and target discovery services to academic and biopharmaceutical partners.

The company operates primarily within the United States while holding international certification in Europe and licensing its technology to partner laboratories across Europe, Australia, and Japan. Its clinical testing workflows are integrated across multiple electronic medical record networks, including Epic and Flatiron Health. The provided text does not state the company's headquarters location.

Summary of the business section of Adaptive Biotechnologies's latest annual report, written by StockData.

Company profile

Company

Legal name
Adaptive Biotechnologies Corp
Founded
2009
Headquarters
Seattle, WA
Address
1165 Eastlake Ave E 98109
Phone
(206) 659-0067
Employees
624, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Washington
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Seattle, Washington

Stock & identifiers

Ticker
ADPT
Exchange
Nasdaq
IPO date
Jun 27, 2019
Shares outstanding
160M, Jul 31, 2026
Public float
$1.39B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1478320
CUSIP
00650F109
ISIN
US00650F1093
FIGI
BBG001J2PFF5
Share class FIGI
BBG001V0GG18
LEI
549300ZTF7OT1FW66Q96
EIN
27-0907024

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Chad M. RobinsCEO and Chairman, Director2,930,518
Julie RubinsteinPresident and COO377,802
Susan BobulskyChief Commercial Officer, MRD387,475
Francis LoChief People Officer223,367
Harlan S. RobinsChief Scientific Officer2,104,458
Sharon BenzenoChief Commercial Ofc Imm Med299,532
Kyle PiskelChief Financial Officer256,725
Katey Einterz OwenDirector66,100
Robert HershbergDirector77,347
Peter M. NeupertDirector255,315
Michelle Renee GriffinDirector15,625
Michael J. PelliniDirector69,690

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.08M$39.60M$4.99M$27$125
FY2024$4.97M$8.35M$2.39M$10$93
FY2023$8.90M$2.75M$4.26M$8$94
FY2022$8.85M-$1.14M$4.32M$13$90
FY2021$8.75M-$6.18M$5.87M$47$100
FY2020$7.13M$24.87M$4.13M$198$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Chad Robins
Chief Executive Officer and Chairman
$698.26K$7.68M–$703.38K$4.95K$9.08M+83%
Kyle Piskel
Chief Financial Officer
$399.95K$2.70M–$203.30K$4.98K$3.31M+157%
Susan Bobulsky
Chief Commercial Officer, MRD
$435.75K$1.88M$997.33K$226.01K$4.48K$3.55M+108%
Harlan Robins
Chief Scientific Officer
$558.65K$7.68M–$270.82K$5.00K$8.51M+87%
Julie Rubinstein
President and Chief Operating Officer
$542.38K$3.78M–$273.18K$4.93K$4.60M+74%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 27, 2019
Offer price
$20.00
Securities offered
15,000,000
Gross proceeds
$300.00M
Exchange
Nasdaq
First trading day
Jun 27, 2019
First-day close
$40.30+101.5%
Lock-up ends (est.)
Dec 24, 2019

“The initial public offering price of our common stock is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 624 full-time employees of which 94 hold medical or doctoral degrees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 3, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 27, 2019IPOInitial public offering priced (424B4 prospectus)
Jun 26, 2019ListingRegistration of securities on an exchange (Form 8-A)
Jun 2, 2011Name changeName changed from Adaptive TCR Corp to Adaptive Biotechnologies Corp

See a number that looks wrong?